Almac Expands UK Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Almac Expands UK Facility
Almac announces further expansion and 229 new jobs


Almac has announced further expansion of its UK facility. Together with the new non-GMP drug development facility at the Craigavon site, the two expansions represent a total investment of £13.7million ($21.5 million), which includes some financial support from Invest Northern Ireland. Both projects are expected to create up to 229 jobs over the next three years according to the press release.

Almac stated that it will focus all production in Northern Ireland with additional equipment and resources in Craigavon. The investment will deliver blending equipment, an automated packing and integrated cartoning line which will enable high volume bulk commercial manufacturing, scheduled to begin in November 2013.

The new 13,400 square-feet formulation-development facility and analytical laboratories at Almac’s Craigavon site are also experiencing growth. This non-GMP facility develops tablet and capsule formulations for new drugs in early-stage development, which have not reached the market. The aim is to enable greater speed in formulation and process development, by creating an environment where development work be done quickly and efficiently and free from the constraints associated with drug manufacturing.

According to Graeme McBurney, president and managing director of the business unit, centralizing and expanding the production in Craigavon will be more cost effective for optimal quality control and distribution, given that Almac’s laxative product has been a success in the UK and Europe. “We are also delighted to see the completion of the new non-GMP facility on site which, alongside Almac’s existing GMP capability, will enable us to operate with improved speed and efficiency in the early stages of projects.”

Enterprise Minister Arlene Foster said, “This investment is good news for Craigavon and will reinforce Northern Ireland’s position in the wider life-sciences sector. The 229 new jobs will deliver almost £5.5 million annually in salaries, bringing an important and positive economic boost which will benefit local people.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here